Steven Anderman, Ariel Ezrachi· ISBN 9780199589951
Special offer terms
Zookal Study Premium
Subscribe & save
By selecting the 'Susbcribe & Save' option you are enrolling in an auto-renewing subscription of Zookal Study Premium. Cancel at anytime.
Auto-Renewal
Your Zookal Study Premium subscription will be renewed each month until you cancel. You consent to Zookal automatically charging your payment method on file $19.99 each month after 1st month free period until you cancel.
How to Cancel
You can cancel your subscription anytime by visiting Manage account page, clicking "Manage subscription" and completing the steps to cancel. Cancellations take effect at the end of the 1st month free period (if applicable) or at the end of the current billing cycle in which your request to cancel was received. Subscription fees are not refundable.
Zookal Study Premium Monthly Subscription Includes:
Ability to post up to ten (10) questions per month.
20% off your textbooks order and free standard shipping whenever you shop online at
textbooks.zookal.com.au
Unused monthly subscription benefits have no cash value, are not transferable, and expire at the end of each month. This means that subscription benefits do not roll over to or accumulate for use in subsequent months.
Payment Methods
Afterpay and Zip Pay will not be available for purchases with Zookal Study Premium subscription added to bag.
$1.00 preauthorisation
You may see a $1.00 preauthorisation by your bank which will disappear from your statement in a few business days..
Email communications
By adding Zookal Study Premium, you agree to receive email communications from Zookal.
In recent times, commercial activities of companies exercising market power through their intellectual property rights have increasingly come under the scrutiny of the EU competition authorities. Intellectual Property and Competition Law: New Frontiers looks at how the leveraging strategies of Microsoft, the patent enhancement strategies of Astra Zeneca and Rambus, and the reverse payment settlements in the pharmaceutical sector have all attracted
competition intervention, and how the courts have been forced to decide whether intellectual property issues are the primary subject matter of the case, or peripheral to that.Drawing on these
judgments, and others, this timely book brings together leading figures from practice and from academia who examine the increasingly complex and often strained relationship between intellectual property and competition law. Focusing primarily on EU law, but with valuable insight into US law, they highlight areas where new frontiers are emerging in the interface between the two, including; refusal to grant access to trade secrets; the new product test in consumer welfare; competition law in the
pharmaceutical sector; standard setting; and FRAND (Fair, Reasonable and Non-Discriminatory terms) commitments. The book also considers the way in which the Commission's proposed changes to the
application of Article 102 EC may impact on the protection of intellectual property rights. In the post-Microsoft litigation era, this timely book captures the range of current thinking on the subject. The impressive list of contributors brings together leading figures from academia and practice, from intellectual property and competition law, and from law and economics, offering unrivalled expert analysis of this complex area.